New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
20:08 EDTHEBHemispherx fatigue drug Ampligen rejected for approval, WSJ reports
An FDA panel voted 8-to-5 against approval of Hemixpherx's (HEB) chronic fatigue drug Ampligen at an FDA Arthritis Advisory Committee Meeting Thursday, according to a Wall Street Journal report. Reference Link
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 11, 2015
08:41 EDTHEBHemispherx Biopharma Europe receives orphan designation by EMA for Ampligen
Hemispherx announces that its European subsidiary, Hemispherx Biopharma Europe, received formal notification from the European Commission approving its Orphan Medicinal Product Application for Ampligen, an experimental therapeutic, to treat Ebola Virus Disease.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use